Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

May 11, 2022

Study Completion Date

January 11, 2024

Conditions
Peripheral T Cell LymphomaTransformed Mycosis Fungoides
Interventions
DRUG

AFM13

weekly intravenous infusions of 200mg

Trial Locations (69)

10019

Center for Lymphoid Malignancies, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

30322

Emory University Clinic/Winship Cancer Institute, Atlanta

35294

University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center), Birmingham

55905

Mayo Clinic, Rochester

70121

Ochsner Clinic Foundation/Precision Cancer Therapies Program, New Orleans

77030

MD Anderson Cancer Center, Houston

90404

University of California Los Angeles (UCLA) Health, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

98109

University of Washington Seattle Cancer Care Alliance, Seattle

Michigan

"University of Michigan Health , Rogel Cancer Center"

Unknown

Royal Adelaide Hospital, Adelaide

Flinders Medical Centre, Bedford Park

Monash Health-Monash Medical Centre, Clayton

Concord Repatriation General Hospital, Concord

Gosford Hospital, Gosford

Linear Clinical Research, Nedlands

Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux

Centre Hospitalier Universitaire de Brest, Brest

CHD Vendée, La Roche-sur-Yon

CHU Pontchaillou, Rennes

Institut Gustave Roussy, Villejuif

Kliniken Essen Sued - Evangelisches Krankenhaus Essen-Werden gGmbH, Essen

University Hospital Leipzig, Leipzig

Universitaetsmedizin Mainz, Mainz

Rotkreuzklinikum Muenchen, München

Ist.Ematologia E Oncologia Medica L.E A.Seragnoli, Bologna

Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia, Brescia

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola

Azienda Ospedaliera Niguarda Ca' Granda, Milan

Azienda Unita Sanitaria Locale di Ravenna - Ospedale S. Maria delle Croci di Ravenna, Ravenna

Szpitale Pomorskie Sp. z o.o.. Szpital Morski im. PCK, Oddzial Hematologii i Transplantologii Szpiku, Gdynia

Pratia MCM Krakow, Krakow

Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warsaw

Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warsaw

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu. Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw

Republic Hospital n.a. V.A. Baranov, Petrozavodsk

First State Saint-Petersburg Pavlov Medical University, Saint Petersburg

GUZ Leningrad Regional Clinical Hospital, Saint Petersburg

Russian Research Institute of Hematology and Transfusiology of the Federal Biomedical Agency, Saint Petersburg

Saratov State Medical University, Saratov

Regional Clinical Hospital, Tula

Chonbuk National University Hospital, Jeonju

Seoul National University Bundang Hospital, Seongnam-si

Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Samsung Medical Center, Seoul

Ulsan University Hospital, Ulsan

Duran I Reynals Hospital Catalan Institute Of Oncology, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital del Mar, Barcelona

Hospital Universitari Vall d'Hebron, Barcelona

Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol, Barcelona

Institut Catala d' Oncologia Girona, Girona

Hospital Universitario 12 de Octubre-Centro de Actividades Ambulatorias, Madrid

Hospital Universitario Fundacion Jimenez Diaz, Madrid

Hospital Universitario Virgen del Rocio, Seville

Institut Catala d'Oncologia Tarragona, Tarragona

Ankara University Faculty of Medicine, Department of Internal Diseases, Hematology Division, Ankara

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim Arastirma Hastanesi Hematoloji Klinigi Ankara, Ankara

Gazi University Faculty of Medicine, Department of Internal Diseases, Ankara

Sağlık Bilimleri Üniversitesi Gülhane Eğitim ve Araştırm Hastanesi, Ankara

Istanbul Universitesi Istanbul Tip Fakultesi Ic Hastaliklari Anabilim Dali Hematoloji Bilim Dali Fatih, Istanbul

Ege University Medical Faculty, Izmir

Kocaeli University Faculty of Medicine, Department of Internal Diseases, Hematology Division, İzmit

Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uyg. ve Egitim Merkezi, Samsun

Tekirdag Namik Kemal Universitesi Saglik Uygulama ve Arastirma Hastanesi, Tekirdağ

KaradenizTeknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Affimed GmbH

INDUSTRY

NCT04101331 - Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides | Biotech Hunter | Biotech Hunter